This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Firms Expecting Clinical Trial Results

Company: Cyclacel Pharmaceuticals (CYCC - Get Report)

Drug/indication: Seliciclib for non-small cell lung cancer

Expected timing: Before year's end

Recent stock performance: At around $1.50, the stock has been cut in half from the $3 level reached in January.

Last January, investors bid up shares of Cyclacel on the publication of research demonstrating that seliciclib was effective against certain lung cancer cells -- in a petri dish. Some of that investor excitement for the stock has ebbed in the subsequent seven months, but could be rekindled if Cyclacel posts positive results from this phase II study in non-small cell lung cancer patients. The phase II study is somewhat unique because it uses a follows a "randomized discontinuation" design that was most famously used to test the initial efficacy of Onyx Pharmaceutical's cancer drug Nexavar. In this case, all lung cancer patients are first treated with seliciclib for six weeks. Patients whose tumors remain stable at a minimum after this run-in treatment phase are then randomized to continue treatment with seliciclib or receive best supportive care. The study's primary endpoint is progression-free survival measured in the randomized portion of the study.
7 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARIA $7.91 0.00%
BMRN $136.84 0.00%
AZN $65.41 0.00%
CORT $6.00 0.00%
CYCC $0.78 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs